TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from ANGLE plc ( (GB:CLBX) ).
CelLBxHealth plc announced an additional subscription by Conifer Management, LLC, on behalf of the Acacia funds, for 40,891,541 new ordinary shares, raising approximately £0.4 million. This additional subscription, part of a larger fundraising effort totaling approximately £8.2 million, will result in Acacia holding 29.9% of the company’s issued share capital. The fundraising, supported by Cavendish Capital Markets Limited and Beech Hill Securities, Inc., is set to enhance CelLBxHealth’s financial position, potentially impacting its market operations and stakeholder interests positively.
The most recent analyst rating on (GB:CLBX) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
Spark’s Take on GB:CLBX Stock
According to Spark, TipRanks’ AI Analyst, GB:CLBX is a Underperform.
ANGLE plc’s overall stock score is primarily influenced by its financial performance and technical analysis. The company faces significant financial challenges with declining revenues and persistent losses, which are reflected in a low financial performance score. Technical indicators suggest bearish momentum, further impacting the stock’s attractiveness. Valuation metrics are also weak, with a negative P/E ratio and no dividend yield, contributing to the low overall score.
To see Spark’s full report on GB:CLBX stock, click here.
More about ANGLE plc
CelLBxHealth plc is a company specializing in circulating tumor cell (CTC) intelligence, providing innovative CTC solutions for research, drug development, and clinical oncology. Their patent-protected Parsortix® platform is designed to harvest CTCs from blood, integrating with existing laboratory instruments for comprehensive analysis, including whole-cell imaging, proteomic profiling, and genomic workflows. The company focuses on product sales, laboratory services, and lab-developed tests, with commercial activities centered around accelerating Parsortix platform adoption and providing clinical trial support and assay development.
Average Trading Volume: 3,149,825
Technical Sentiment Signal: Sell
Current Market Cap: £3.71M
See more insights into CLBX stock on TipRanks’ Stock Analysis page.